ORIC Pharmaceuticals, Inc. (FRA:4TZ)
Germany · Delayed Price · Currency is EUR | Market Cap | 800.10M +165.6% |
| Revenue (ttm) | n/a |
| Net Income | -117.27M |
| EPS | -1.22 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 6.44 |
| Previous Close | 6.79 |
| Day's Range | 6.38 - 6.44 |
| 52-Week Range | 6.10 - 13.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About ORIC Pharmaceuticals
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutat... [Read more]
News
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address m...
Oric Pharmaceuticals moved to Buy rating at Goldman Sachs
Goldman Sachs moved Oric Pharmaceuticals (ORIC) to a Buy rating and $15 price target from its Early Stage Biotech designation. The company’s clinical data which demonstrated a “potentially differentia...
ORIC Pharmaceuticals Slides: Company presentation
ORIC Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Oric Pharmaceuticals price target lowered to $16 from $17 at Citi
Citi lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $16 from $17 and keeps a Buy rating on the shares.
Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)
“The first quarter marked a pivotal step for ORIC as we selected our Phase 3 dose for rinzimetostat, reported data supporting a potential best-in-disease profile, and moved toward the initiation…
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026
ORIC Pharmaceuticals Earnings release: Q1 2026
ORIC Pharmaceuticals released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
ORIC Pharmaceuticals Quarterly report: Q1 2026
ORIC Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 4, 2026.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address me...
ORIC Pharmaceuticals Proxy statement: Proxy filing
ORIC Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
ORIC Pharmaceuticals Proxy statement: Proxy filing
ORIC Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR
ORIC Pharmaceuticals (ORIC) “announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research Annual Meeting highlighting the potential of rinzimetostat...
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC). The investigation focuses on O...
Oric selloff brings attractive entry point, says H.C. Wainwright
H.C. Wainwright analyst Robert Burns says the pullback this week in shares of Oric Pharmaceuticals (ORIC) provides an attractive entry point. The firm says the market overreacted to Oric’s metastatic…
Oric Pharmaceuticals should be bought on selloff, says Citi
Citi recommends using today’s weakness in shares of Oric Pharmaceuticals (ORIC) as a buying opportunity. The 30% pullback is “overdone and misguided,” the analyst tells investors in a research note.
Oric Pharmaceuticals price target lowered to $17 from $20 at Wedbush
Wedbush analyst David Nierengarten lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $17 from $20 and keeps an Outperform rating on the shares. Oric’s Phase 1 prostate cancer…
Oric’s rinzi efficacy ‘comparable’ to Pfizer’s mevro, says Cantor Fitzgerald
Oric Pharmaceuticals (ORIC) presented a Phase 1 dose optimization update for rinzimetostat combined with darolutamide in mCRPC, alongside details of the upcoming Phase 3 trial, Cantor tells investors ...
Oric selloff on cancer data ‘appears exaggerated,’ says JonesResearch
JonesResearch says the market overreacted yesterday to Oric Pharmaceuticals (ORIC)’ Phase 1 prostate cancer data. Oric reported efficacy that was in line with Pfizer’s (PFE) mevrometostat while demons...
Oric Pharmaceuticals announces rinzimetostat, ORIC-944, program update
ORIC Pharmaceuticals (ORIC) “announced a rinzimetostat (ORIC-944) program update and potential best-in-disease efficacy and safety data from the Phase 1b trial of once daily rinzimetostat in combinati...
ORIC Pharmaceuticals Transcript: Study update
Rinzimetostat at 400 mg daily with darolutamide showed strong efficacy and a highly differentiated safety profile in mCRPC, supporting its selection as the phase III dose. Landmark RPFS and ctDNA responses were robust, and safety was superior to competitor regimens, positioning it for significant commercial potential.
ORIC Pharmaceuticals Press release: Study update
ORIC Pharmaceuticals issued a press release on March 31, 2026, disclosing material business information to investors.
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...